Waitaki Bioscience has introduced StimuCal, a patent-pending, concentrated source of natural calcium with bone stimulating protein. Many calcium supplements are designed to be absorbed rapidly. However, a number of leading researchers have identified a link between calcium supplementation and an increased risk of heart attack, which is thought to be directly related to the rapid spiking of blood calcium levels following ingestion of the supplement.

Rigorously tested in an independently designed, randomized, placebo-controlled trial of 100 postmenopausal women conducted by the Department of Medicine at the University of Auckland, New Zealand, StimuCal was found to produce lower peak blood calcium levels than either calcium carbonate or calcium citrate while maintaining an identical effect on markers of bone turnover. The women were randomized to receive 1,000 mg per day of calcium as either StimuCal, calcium carbonate, calcium citrate or placebo. Acute changes in blood calcium levels were monitored over an 8-hour period and key biochemical markers of bone turnover were measured at baseline and at three months as a measure of efficacy. Peak blood calcium levels after ingestion of StimuCal were 45-49% lower than peak blood calcium levels after ingestion of the same amount of calcium from either calcium carbonate or calcium citrate.

For more information: www.stimucal.com